Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Oncology Strategy: An Investment Starts To Pay Off

Executive Summary

With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.

Advertisement

Related Content

Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race
With The End Of Pfizergan, Pfizer Has To Grow It Alone
Among New Drug Launches, Oncology Scores Big While CV Lags
Pfizer To Spend 2016 Playing Catch Up In Big Therapeutic Categories
Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics
Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
Pfizer’s Dolsten Explains Why The Big Pharma Can Win The Immuno-Oncology Marathon
Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs
Pfizer’s Crizotinib Eases Past FDA With Targeted Population

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056954

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel